Articles tagged with Breast Cancer
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has successfully enrolled over 108,000 women worldwide for a randomized controlled trial comparing 2D and 3D mammography. The study aims to determine whether 3D mammography is more effective in reducing advanced breast cancer risk.
Researchers at Case Western Reserve University have made a groundbreaking discovery about the molecular switches within the estrogen receptor protein that contribute to breast cancer. The study's findings offer new tools and ideas for developing more effective treatments for this devastating disease.
A study found that RAD51 testing can predict which patients with early-stage HER2-negative breast cancer may respond to neoadjuvant therapy. Patients with high RAD51 protein levels showed a higher response rate to PARP inhibitor treatment, suggesting the potential for personalized treatment strategies.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
A recent study published in Nature Medicine found that AI significantly improves breast cancer detection rates, detecting an additional cancer case per 1,000 women screened. The results show improved efficiency without increasing false positives or unnecessary follow-ups.
Early detection of breast cancer can lead to less intensive treatments, saving the Canadian healthcare system $459.6M over women's lifetimes and 3,499 breast cancer deaths. Screening mammograms and diagnostics costs are easily offset by earlier stage treatment.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Weill Cornell Medicine has received a $2.3 million CDC grant to enhance care coordination for young breast cancer survivors, focusing on racially and socio-economically diverse groups to reduce symptom burden and improve survival outcomes.
Scientists cultivate stable tumor organoids directly from blood samples of breast cancer patients, revealing a molecular signaling pathway that ensures cancer cell survival and resistance to therapy. The team develops an approach to specifically eliminate these tumor cells in lab experiments.
A case-control study found a link between advanced breast cancer stage and prevalent cardiovascular disease, with hormone receptor-positive and ERBB2-negative disease being more affected. Future studies are needed to confirm these findings and investigate interventions to improve patient outcomes.
Research from the University of Texas M. D. Anderson Cancer Center suggests that individuals with pre-existing cardiovascular disease are more likely to have advanced or metastatic breast cancer. The study found a 10% increased risk of CVD in patients with late-stage breast cancer compared to those with early-stage cancer.
Genetic testing for cancer risk should always include healthcare providers and genetic counseling to ensure users fully understand their results and receive proper guidance. The authors call on the FDA to provide clear rules for using these tests, particularly for minors.
A cohort study found a decrease in localized invasive breast cancer and regional invasive breast cancer since the 2009 guideline changes, but no decrease in advanced cancer stages. Further research is needed to understand these trends.
Researchers discovered that aggressive breast cancer prompts nearby immune cells to build 'molecular bridges' between themselves, suppressing the immune response. An antibody treatment that blocks these bridges was shown to restore the immune system's ability to attack with force, inhibiting tumor growth in a mouse model.
Researchers developed biodegradable polymeric nanoparticles that selectively target cancer cells with two approved drug pairs for skin and breast cancers. The treatment showed significantly enhanced therapeutic effects, reduced tumor size, and prolonged median survival in mice.
A recent study found that nearly two-fifths of women aged 40-49 did not receive biennial mammography screening, highlighting significant gaps in early detection. To optimize breast cancer detection, ensuring equitable adherence to U.S. Preventive Services Task Force recommendations is crucial.
Researchers at UC Davis Comprehensive Cancer Center have identified a biomarker called TRIM37 associated with aggressive triple-negative breast cancer (TNBC) in Black women. This finding may help develop predictive biomarkers to improve TNBC diagnosis and prognosis, particularly for early-stage patients. TRIM37 overexpression is linked...
Researchers at City of Hope have developed a blood test to identify patients with precancerous esophageal disease, offering promise for improved early screening. Additionally, the study discovered a mechanism linking aging and cellular dysfunction in breast cancer, suggesting potential biomarkers for early detection.
A pioneering study has unlocked precision medicine for breast cancer, providing a detailed roadmap of the disease's molecular evolution. The research enables targeted therapies tailored to individual tumors' molecular fingerprints, elevating survival rates and improving patient outcomes.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
A randomized clinical trial found that cannabidiol (CBD) significantly reduced anxiety levels 2-4 hours after ingestion in women with advanced breast cancer. CBD's anxiolytic effect suggests its potential as a treatment for scan-related anxiety.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
A new screening method combining laser analysis with AI identifies patients with breast cancer in its earliest stage, stage 1a. This non-invasive technique reveals subtle changes in the bloodstream that occur during the initial phases of the disease, outperforming existing early detection strategies.
A multimodal machine learning model outperformed clinical and genomic models in predicting outcomes for HR-positive, HER2-negative breast cancer patients receiving CDK4/6 inhibitor combinations. The model integrated clinical and genomic factors to identify high-risk patients with a 6.5-fold difference in hazard ratio.
A study found that adding anthracyclines to taxane-based chemotherapy improved survival outcomes for HR-positive, HER2-negative breast cancer patients with high risk of recurrence. The OncotypeDX genomic test helped identify which patients could benefit from the addition.
The ZEST trial found that patients with detectable circulating tumor DNA (ctDNA) were more likely to have aggressive disease characteristics. To improve outcomes, researchers recommend starting ctDNA testing during treatment rather than waiting for completion, and targeting high-risk patients with tailored therapies.
A new study shows targeted delivery of energy-disrupting gene therapy using nanoparticles shrinks glioblastoma brain tumors and aggressive breast cancer tumors in mice. The technology, mLumiOpto, induces light-activated electrical currents inside cells to disrupt mitochondria, leading to programmed cell death and DNA damage.
The COMET trial found that active monitoring is a viable option for some patients with low-risk ductal carcinoma in situ (DCIS), with similar two-year invasive ipsilateral breast cancer recurrence rates compared to usual care. Active monitoring involves close patient monitoring with surgery reserved for those who develop cancer.
Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to those who received upfront treatment. The study found no significant differences in health-related quality of life between the two groups over time.
For patients with 'good-risk' ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast. The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen.
The BIG 2-04 MRC SUPREMO clinical trial found no significant difference in overall survival between patients who received chest wall irradiation (CWI) and those who did not. CWI's impact was also shown to be clinically insignificant in reducing chest wall recurrence.
A randomized study found that active monitoring for low-risk ductal carcinoma in situ did not increase invasive cancer risk compared to guideline-concordant care. Women on active monitoring had comparable rates of disease recurrence and survival.
Artificial intelligence is enhancing breast cancer risk prediction through mammographic analysis, uncovering key features that predict breast cancer risk. These AI-generated features may inform personalized screening strategies, such as more frequent or less frequent screenings for women at high or low risk of breast cancer.
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
Patients with germline BRCA mutations who underwent bilateral risk-reducing mastectomy and/or salpingo-oophorectomy had lower rates of recurrence, secondary malignancies, and death. Risk-reducing surgeries improved survival outcomes among young BRCA-mutation carriers with a prior history of early-onset breast cancer.
The OlympiA trial found that olaparib significantly improves survival outcomes in patients with high-risk, BRCA-positive breast cancer. After a median follow-up of 6.1 years, patients treated with olaparib showed better rates of invasive and distant disease-free survival compared to those who received placebo.
The EMBER-3 clinical trial showed that imlunestrant improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer, particularly those with ESR1 mutations. The combination of imlunestrant and abemaciclib also demonstrated a significant reduction in risk of progression or death.
A study by Tulane University researchers found that tumors in female fruit flies grew 2.5 times larger than those in male fruit flies due to sex-based differences in immune response. The stronger innate immune response in females accelerated tumor growth.
The study found a significant increase in late-stage breast cancer diagnoses among U.S. women, with annual percentage increases of up to 2.9% between 2004 and 2021. The researchers attribute the trend to factors such as lack of national screening programs, inconsistent guidelines, and increasing obesity rates.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
The 47th San Antonio Breast Cancer Symposium is the world's largest breast cancer research conference, attracting over 11,000 attendees from 102 countries. The event showcases groundbreaking discoveries in drug development and advances care for underserved populations.
A study published in Cell found a common variant of the PCSK9 gene increases the risk of breast cancer metastasis by 22% compared to those without it. Researchers propose using an antibody targeting PCSK9 to suppress this variant and reduce metastatic disease.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
A study suggests that low doses of the commonly prescribed hair loss treatment minoxidil are safe and effective for regrowing hair in most breast cancer patients. The researchers found that all participants who took a low dose of oral minoxidil saw improvements in hair growth or stabilization within three to six months.
A University of Liverpool study uncovers a key mechanism driving breast cancer invasion and drug resistance, revealing a critical 'crosstalk' between HER2 and αVβ6 integrin molecules. The research highlights the importance of targeting the RAB5/RAB7A/GDI2 module to prevent or delay treatment resistance.
Scientists have created a living cell therapy that can navigate to specific organs using a
A new study improves breast cancer risk prediction by analyzing up to three years of previous mammograms, identifying individuals at high risk 2.3 times more accurately than the standard method. The AI method considers subtle changes in mammogram images and holds up well across diverse settings.
A self-pay, AI-enhanced breast cancer screening program was offered to patients across 10 clinical practices, resulting in a 43% higher cancer detection rate among enrolled women. The AI-powered program attributed 21% of the increase in cancer detection, with higher-risk patients choosing to enroll more frequently.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
A groundbreaking phase one clinical trial explores a novel cell-based immunotherapy for breast cancer, demonstrating significant shrinkage of tumors and minimal side effects. The treatment leverages dendritic cells to trigger an organized immune system attack on cancer, offering hope for replacing or reducing the need for chemotherapy.
A study published in Nature reveals that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer. The liver converts fructose into usable nutrients for cancer cells, a finding that could lead to new treatment avenues.
A new study has solved a years-old mystery about which patients with aggressive breast cancer are helped by a targeted cancer treatment. The researchers found that low levels of the protein IGFBP7 can predict which patients will benefit from the treatment, providing hope for its continued development.
Breast cancer cells can live for years in bone marrow after remission, leading to disease recurrence in approximately 40% of patients. A study found that mesenchymal stem cells support the cancer cells by donating essential proteins, making them more aggressive and drug-resistant.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.